Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping the future of medicine and genetics.

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day.

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...